Brimonidine Tartrate

Specifications

70359-46-5CAS Number

629-848-5EC Number

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acidIUPAC Name

C15H16BrN5O6Chemical Formula

442.22 g/molMolecular Weight

BRIMONIDINE TARTRATE; 70359-46-5; Alphagan; Brominide tartrate; Qoliana; Lumify; Bromoxidine tartrate; Alphagan P; AGN 190342-LF; AGN-190342-LF; mirvaso; 4S9CL2DY2H; UK-14304-18; OCU300; OCU-300; AGN-190342LF; Cd-07805; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); CD07805/47; UK-1430418; CD-07805/47; DTXSID70911371; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate (1:1); SIMBRINZA COMPONENT BRIMONIDINE TARTRATE; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Brymont; Ratio Brimonidine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1); RefChem:58238; DTXCID501340408; LUMIFY Redness Reliever Eye Drops; AGN190342; LUMIFY PRESERVATIVE FREE EYE DROPS; UK14,308; UK 14,308; UK-14,308; UK14,30418; UK 14,30418; 5-bromo-6-(imidazolidinylideneamino)quinoxaline; UK 14,304 18; UK-14,304-18; Brimonidine Tartrate ophthalmic solution, 0.15%; 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline d-tartrate; BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%; 6-Quinoxalinamine, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-,(2R,3R)-2,3-dihydroxybutanedioate(1:1); 629-848-5; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; AGN-190342; CHEBI:51157; Brimonidine tartarate; Brimonidine L-Tartrate; MFCD07773072; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate; 79570-19-7; (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate; brimonidine Purite; Brimonidine-D-tartrate; Brimonidine tartrate [USAN]; UNII-4S9CL2DY2H; Alphagan-P; AGN 190342LF; Brimonidine tartrate [USAN:JAN]; Alphagan (TN); 5-bromo-N-; Brimonidine tartrate CRS; C15H16BrN5O6; HY-B0659AR; orb1300783; CHEMBL1200389; SCHEMBL29378438; EX-A5415A; HY-B0659A; Brimonidine tartrate (JAN/USAN); QZHBYNSSDLTCRG-LREBCSMRSA-N; Brimonidine (tartrate) (Standard); BRIMONIDINE TARTRATE [JAN]; GLXC-07935; HMS3715P18; BRIMONIDINE TARTRATE [VANDF]; BRIMONIDINE TARTRATE [MART.]; BRIMONIDINE TARTRATE [USP-RS]; BRIMONIDINE TARTRATE [WHO-DD]; AKOS016845265; CCG-221278; CS-4496; FB32174; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine(2R,3R)-2,3-dihydroxysuccinate; AS-18083; BRIMONIDINE TARTRATE [ORANGE BOOK]; SY065942; BRIMONIDINE TARTRATE [EP MONOGRAPH]; BRIMONIDINE TARTRATE [USP MONOGRAPH]; T6422; YUVEZZI COMPONENT BRIMONIDINE TARTRATE; COMBIGAN COMPONENT BRIMONIDINE TARTRATE; D02076; (4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine tartrate; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine D-tartrate; (2R,3R)-2,3-Dihydroxybutanedioic acid--5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (1/1); (2R,3R)-2,3-dihydroxybutanedioic acid; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 109826-56-4Synonyms